A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

In May 2025, the Journal for ImmunoTherapy of Cancer published a pioneering study entitled "NeoPred: dual-phase CT AI forecasts pathologic response to ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...